303 related articles for article (PubMed ID: 9233776)
1. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents.
Brown R; Hirst GL; Gallagher WM; McIlwrath AJ; Margison GP; van der Zee AG; Anthoney DA
Oncogene; 1997 Jul; 15(1):45-52. PubMed ID: 9233776
[TBL] [Abstract][Full Text] [Related]
2. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
3. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.
Aebi S; Fink D; Gordon R; Kim HK; Zheng H; Fink JL; Howell SB
Clin Cancer Res; 1997 Oct; 3(10):1763-7. PubMed ID: 9815561
[TBL] [Abstract][Full Text] [Related]
4. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin.
Moreland NJ; Illand M; Kim YT; Paul J; Brown R
Cancer Res; 1999 May; 59(9):2102-6. PubMed ID: 10232595
[TBL] [Abstract][Full Text] [Related]
5. Transient mismatch repair gene transfection for functional analysis of genetic hMLH1 and hMSH2 variants.
Brieger A; Trojan J; Raedle J; Plotz G; Zeuzem S
Gut; 2002 Nov; 51(5):677-84. PubMed ID: 12377806
[TBL] [Abstract][Full Text] [Related]
6. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy.
Samimi G; Fink D; Varki NM; Husain A; Hoskins WJ; Alberts DS; Howell SB
Clin Cancer Res; 2000 Apr; 6(4):1415-21. PubMed ID: 10778972
[TBL] [Abstract][Full Text] [Related]
7. Deficient MGMT and proficient hMLH1 expression renders gallbladder carcinoma cells sensitive to alkylating agents through G2-M cell cycle arrest.
Sato K; Kitajima Y; Kohya N; Miyoshi A; Koga Y; Miyazaki K
Int J Oncol; 2005 Jun; 26(6):1653-61. PubMed ID: 15870882
[TBL] [Abstract][Full Text] [Related]
8. Loss of DNA mismatch repair in acquired resistance to cisplatin.
Aebi S; Kurdi-Haidar B; Gordon R; Cenni B; Zheng H; Fink D; Christen RD; Boland CR; Koi M; Fishel R; Howell SB
Cancer Res; 1996 Jul; 56(13):3087-90. PubMed ID: 8674066
[TBL] [Abstract][Full Text] [Related]
9. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
[TBL] [Abstract][Full Text] [Related]
10. Activity of a trinuclear platinum complex in human ovarian cancer cell lines sensitive and resistant to cisplatin: cytotoxicity and induction and gene-specific repair of DNA lesions.
Colella G; Pennati M; Bearzatto A; Leone R; Colangelo D; Manzotti C; Daidone MG; Zaffaroni N
Br J Cancer; 2001 May; 84(10):1387-90. PubMed ID: 11355952
[TBL] [Abstract][Full Text] [Related]
11. Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells.
Branch P; Masson M; Aquilina G; Bignami M; Karran P
Oncogene; 2000 Jun; 19(28):3138-45. PubMed ID: 10918568
[TBL] [Abstract][Full Text] [Related]
12. Expression of the DNA mismatch repair proteins hMLH1 and hPMS2 in normal human tissues.
Fink D; Nebel S; Aebi S; Zheng H; Kim HK; Christen RD; Howell SB
Br J Cancer; 1997; 76(7):890-3. PubMed ID: 9328148
[TBL] [Abstract][Full Text] [Related]
13. The role of DNA mismatch repair in platinum drug resistance.
Fink D; Nebel S; Aebi S; Zheng H; Cenni B; Nehmé A; Christen RD; Howell SB
Cancer Res; 1996 Nov; 56(21):4881-6. PubMed ID: 8895738
[TBL] [Abstract][Full Text] [Related]
14. Mutations in mismatch repair genes are involved in the neoplastic transformation of human breast epithelial cells.
Balogh GA; Russo IH; Russo J
Int J Oncol; 2003 Aug; 23(2):411-9. PubMed ID: 12851690
[TBL] [Abstract][Full Text] [Related]
15. Loss of DNA mismatch repair imparts defective cdc2 signaling and G(2) arrest responses without altering survival after ionizing radiation.
Yan T; Schupp JE; Hwang HS; Wagner MW; Berry SE; Strickfaden S; Veigl ML; Sedwick WD; Boothman DA; Kinsella TJ
Cancer Res; 2001 Nov; 61(22):8290-7. PubMed ID: 11719462
[TBL] [Abstract][Full Text] [Related]
16. Identification of a second MutL DNA mismatch repair complex (hPMS1 and hMLH1) in human epithelial cells.
Leung WK; Kim JJ; Wu L; Sepulveda JL; Sepulveda AR
J Biol Chem; 2000 May; 275(21):15728-32. PubMed ID: 10748105
[TBL] [Abstract][Full Text] [Related]
17. ATM-mediated stabilization of hMutL DNA mismatch repair proteins augments p53 activation during DNA damage.
Luo Y; Lin FT; Lin WC
Mol Cell Biol; 2004 Jul; 24(14):6430-44. PubMed ID: 15226443
[TBL] [Abstract][Full Text] [Related]
18. The cellular basis of the efficacy of the trinuclear platinum complex BBR 3464 against cisplatin-resistant cells.
Perego P; Gatti L; Caserini C; Supino R; Colangelo D; Leone R; Spinelli S; Farrell N; Zunino F
J Inorg Biochem; 1999 Oct; 77(1-2):59-64. PubMed ID: 10626355
[TBL] [Abstract][Full Text] [Related]
19. DNA mismatch repair enzyme activity and gene expression in prostate cancer.
Yeh CC; Lee C; Dahiya R
Biochem Biophys Res Commun; 2001 Jul; 285(2):409-13. PubMed ID: 11444857
[TBL] [Abstract][Full Text] [Related]
20. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer.
Strathdee G; MacKean MJ; Illand M; Brown R
Oncogene; 1999 Apr; 18(14):2335-41. PubMed ID: 10327053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]